$0.30
-0.03 (-10.36%)
Open$0.33
Previous Close$0.33
Day High$0.33
Day Low$0.29
52W High$15.82
52W Low$0.32
Volume—
Avg Volume780.3K
Market Cap7.73M
P/E Ratio—
EPS$-9.85
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,987.2% upside
Current
$0.30
$0.30
Target
$12.09
$12.09
$6.99
$12.09 avg
$15.02
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.42M | 3.23M | 3.00M |
| Net Income | -386,907 | -351,594 | -373,147 |
| Profit Margin | -11.3% | -10.9% | -12.5% |
| EBITDA | -622,705 | -634,407 | -526,103 |
| Free Cash Flow | -366,603 | -274,517 | -229,625 |
| Rev Growth | +21.7% | +15.6% | +5.5% |
| Debt/Equity | 0.38 | 0.31 | 0.42 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |